Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 14.3% in March

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 221,900 shares, a growth of 14.3% from the March 15th total of 194,200 shares. Approximately 1.9% of the shares of the company are sold short. Based on an average daily volume of 224,000 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Trading of Chemomab Therapeutics

Large investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. bought a new stake in Chemomab Therapeutics during the first quarter worth $52,000. Renaissance Technologies LLC bought a new stake in shares of Chemomab Therapeutics during the 1st quarter worth $134,000. Citadel Advisors LLC acquired a new stake in Chemomab Therapeutics in the third quarter valued at about $53,000. Boothbay Fund Management LLC grew its position in Chemomab Therapeutics by 38.1% in the fourth quarter. Boothbay Fund Management LLC now owns 51,608 shares of the company’s stock valued at $165,000 after acquiring an additional 14,237 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Chemomab Therapeutics during the first quarter worth about $48,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Trading Down 9.5 %

NASDAQ CMMB traded down $0.07 during midday trading on Tuesday, hitting $0.66. The company had a trading volume of 37,664 shares, compared to its average volume of 207,249. The firm has a 50-day moving average price of $0.73 and a 200-day moving average price of $0.66. The company has a market capitalization of $7.30 million, a PE ratio of -0.31 and a beta of 0.36. Chemomab Therapeutics has a twelve month low of $0.42 and a twelve month high of $1.89.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same period last year, the company posted ($0.72) earnings per share. On average, equities analysts anticipate that Chemomab Therapeutics will post -1.2 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CMMB shares. Roth Mkm reissued a “buy” rating and set a $7.00 target price on shares of Chemomab Therapeutics in a report on Tuesday, December 19th. Roth Capital reiterated a “buy” rating on shares of Chemomab Therapeutics in a research note on Tuesday, December 19th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).